{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T20:34:46Z","timestamp":1770064486893,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the earmarked fund for the China Agriculture Research System","award":["CARS-37"],"award-info":[{"award-number":["CARS-37"]}]},{"name":"the National Science & Technology Pillar Program during the Twelfth Five-year Plan Period","award":["2015BAD11B01"],"award-info":[{"award-number":["2015BAD11B01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Myrislignan is a natural product from Myristica sp. with diverse pharmacological activities. Recently, the anti-<jats:italic>Toxoplasma gondii<\/jats:italic> (<jats:italic>T. gondii<\/jats:italic>) activity of myrislignan has been proposed, and <jats:italic>in vivo<\/jats:italic> studies of its pharmacokinetics in BALB\/c mice are necessary to further evaluate the clinical effects of myrislignan.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In this study, a sensitive liquid chromatography-tandem mass spectrometry (LC-MS\/MS) method was developed and validated to quantify myrislignan levels in mouse plasma using dehydrodiisoeugenol as an internal standard (IS) in positive ion mode. Chromatographic separation of the analytes was achieved using an ACE Ultracore Super C18 analytical column (2.5\u00a0\u03bcm, 2.1\u2009\u00d7\u200950 mm) at 30\u00a0\u00b0C. A gradient mobile phase consisting of water (0.1\u2009% formic acid) and acetonitrile (0.1\u2009% formic acid) was delivered at a flow rate of 0.4 mL\/min. Myrislignan and the IS eluted at 1.42 and 1.71\u00a0min, respectively. A good excellent linear response across the concentration range of 1-1000 ng\/mL was achieved (<jats:italic>r<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20090.9973). The lower limit of quantification (LLOQ) was 1 ng\/mL, and the inter- and intra-day accuracy and precision of the method showed relative standard deviations (RSDs) less than 10\u2009%. The method was applied to examine the pharmacokinetics of myrislignan in mouse plasma following a single oral administration of 200\u00a0mg\/kg or intraperitoneal administration of 50\u00a0mg\/kg myrislignan, and the bioavailability (F) of orally administered myrislignan was only 1.97\u2009% of the bioavailability of intraperitoneally administered myrislignan.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>A rapid and sensitive LC-MS\/MS method has been was developed, validated and successfully used to determine myrislignan levels in mice after oral or intraperitoneal administration. This study is the first to report the pharmacokinetic parameters of myrislignan in mice and to compare its pharmacokinetics after oral and intraperitoneal administration, which will be useful for further research on the administration of myrislignan in animals and humans.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12917-021-02990-y","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T09:04:23Z","timestamp":1629104663000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Determination of myrislignan levels in BALB\/c mouse plasma by LC-MS\/MS and a comparison of its pharmacokinetics after oral and intraperitoneal administration"],"prefix":"10.1186","volume":"17","author":[{"given":"Jili","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongfei","family":"Si","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jichao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biqing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuzheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,16]]},"reference":[{"key":"2990_CR1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/0378-8741(94)90105-8","volume":"42","author":"C Van Gils","year":"1994","unstructured":"Van Gils C, Cox PA. Ethnobotany of nutmeg in the Spice Islands. J Ethnopharmacol. 1994;42:117\u201324.","journal-title":"J Ethnopharmacol"},{"key":"2990_CR2","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/(SICI)1099-1573(199906)13:4<344::AID-PTR436>3.0.CO;2-E","volume":"13","author":"OA Olajide","year":"1999","unstructured":"Olajide OA, Ajayi FF, Ekhelar AI, Awe SO, Makinde JM, Alada AR. Biological effects of Myristica fragrans (nutmeg) extract. Phytother Res. 1999;13:344\u20135.","journal-title":"Phytother Res"},{"key":"2990_CR3","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1089\/jmf.2006.9.395","volume":"9","author":"B Narasimhan","year":"2006","unstructured":"Narasimhan B, Dhake AS. Antibacterial principles from Myristica fragrans seeds. J Med Food. 2006;9:395\u20139.","journal-title":"J Med Food"},{"key":"2990_CR4","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S1995-7645(12)60042-X","volume":"5","author":"SP Piaru","year":"2012","unstructured":"Piaru SP, Mahmud R, Majid AMA, Nassar ZDM. Antioxidant and antiangiogenic activities of the essential oils of Myristica fragrans and Morinda citrifolia. Asian Pac J Trop Med. 2012;5:294\u20138.","journal-title":"Asian Pac J Trop Med"},{"key":"2990_CR5","first-page":"206","volume":"37","author":"JW Lee","year":"2006","unstructured":"Lee JW, Choi YH, Yoo MY, Choi SU, Hong KS, Lee BH, et al. Inhibitory effects of the seed extract of Myristicaceae semen on the proliferation of human tumour cell lines (II). Korean J Pharmacogn. 2006;37:206\u201311.","journal-title":"Korean J Pharmacogn"},{"key":"2990_CR6","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1055\/s-2000-8594","volume":"66","author":"CC Lima","year":"2000","unstructured":"Lima CC, Criddle DN, Coelho-de-Souza AN, Monte FJ, Jaffar M, Leal-Cardoso JH. Relaxant and antispasmodic actions of methyleugenol on guinea-pig isolated ileum. Planta Med. 2000;66:408\u201311.","journal-title":"Planta Med"},{"key":"2990_CR7","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/0378-8741(90)90054-W","volume":"29","author":"J Janssens","year":"1990","unstructured":"Janssens J, Laekeman GM, Pieters LA, Totte J, Herman AG, Vlietinck AJ. Nutmeg oil: identification and quantitation of its most active constituents as inhibitors of platelet aggregation. J Ethnopharmacol. 1990;29:179\u201388.","journal-title":"J Ethnopharmacol"},{"key":"2990_CR8","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1080\/00021369.1973.10860739","volume":"37","author":"A Isogai","year":"1973","unstructured":"Isogai A, Murakoshi S, Suzuki A, Tamura S. Isolation from nutmeg of growth inhibitory substances to silkworm larvae. Agric Biol Chem. 1973;37:889\u201395.","journal-title":"Agric Biol Chem"},{"key":"2990_CR9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.foodchem.2014.09.170","volume":"173","author":"GY Cao","year":"2015","unstructured":"Cao GY, Xu W, Yang XW, Gonzalez FJ, Li F. New neolignans from the seeds of Myristica fragrans that inhibit nitric oxide production. Food Chem. 2015;173:231\u20137.","journal-title":"Food Chem"},{"key":"2990_CR10","first-page":"122","volume":"23","author":"KH Shin","year":"1990","unstructured":"Shin KH, Woo WS. Inhibition and induction of hepatic mixed function oxidase by phenylpropanoids from the seeds of Myristica fragrans. Han\u2019guk Saenghwa Hakhoechi. 1990;23:122\u20137.","journal-title":"Han\u2019guk Saenghwa Hakhoechi"},{"key":"2990_CR11","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1021\/acs.jproteome.7b00901","volume":"17","author":"XN Yang","year":"2018","unstructured":"Yang XN, Liu XM, Fang JH, Zhu X, Yang XW, Xiao XR, et al. PPARalpha mediates the hepatoprotective effects of nutmeg. J Proteome Res. 2018;17:1887\u201397.","journal-title":"J Proteome Res"},{"key":"2990_CR12","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1002\/ptr.3707","volume":"26","author":"H Jin","year":"2012","unstructured":"Jin H, Zhu ZG, Yu PJ, Wang GF, Zhang JY, Li JR, et al. Myrislignan attenuates lipopolysaccharide-induced inflammation reaction in murine macrophage cells through inhibition of NF-kappaB signalling pathway activation. Phytother Res. 2012;26:1320\u20136.","journal-title":"Phytother Res"},{"key":"2990_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s11418-016-1029-6","volume":"71","author":"X Lu","year":"2017","unstructured":"Lu X, Yang L, Chen J, Zhou J, Tang X, Zhu Y, et al. The action and mechanism of myrislignan on A549 cells in vitro and in vivo. J Nat Med. 2017;71:76\u201385.","journal-title":"J Nat Med"},{"key":"2990_CR14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1080\/10575639608044906","volume":"8","author":"M Miyazawa","year":"1996","unstructured":"Miyazawa M, Kasahara H, Kameoka H. Antifungal activities of 8-O-40-neolignans from Myristica fragrans. Nat Prod Lett. 1996;8:271\u20133.","journal-title":"Nat Prod Lett"},{"key":"2990_CR15","first-page":"4","volume":"287","author":"A Matsumoto","year":"1991","unstructured":"Matsumoto A, Matsumoto T, Tokuda H. Lignans from mace as neoplasm inhibitors. Jpn Kokai Tokkyo Koho. 1991;287:4.","journal-title":"Jpn Kokai Tokkyo Koho"},{"key":"2990_CR16","first-page":"818","volume":"8","author":"K Nakajima","year":"1999","unstructured":"Nakajima K, Yamazaki T, Kawashima K, Shinho Y, Kurashige T, Nohara T, et al. Vascular smooth muscle contraction inhibitors from Myristica. Jpn Kokai Tokkyo Koho. 1999;8:818.","journal-title":"Jpn Kokai Tokkyo Koho"},{"key":"2990_CR17","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1055\/s-0030-1249810","volume":"76","author":"XW Yang","year":"2010","unstructured":"Yang XW, Huang X, Ma L, Wu Q, Xu W. The intestinal permeability of neolignans from the seeds of Myristica fragrans in the Caco-2 cell monolayer model. Planta Med. 2010;76:1587\u201391.","journal-title":"Planta Med"},{"key":"2990_CR18","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3390\/molecules21020134","volume":"21","author":"N Wu","year":"2016","unstructured":"Wu N, Xu W, Cao GY, Yang YF, Yang XB, Yang XW. The blood-brain barrier permeability of lignans and malabaricones from the seeds of Myristica fragrans in the MDCK-pHaMDR cell monolayer model. Molecules. 2016;21:134.","journal-title":"Molecules"},{"key":"2990_CR19","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/bmc.975","volume":"22","author":"F Li","year":"2008","unstructured":"Li F, Yang X. Quantification of myrislignan in rat plasma by solid-phase extraction and reversed-phase high-performance liquid chromatography. Biomed Chromatogr. 2008;22:601\u20135.","journal-title":"Biomed Chromatogr"},{"key":"2990_CR20","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/chromsci\/bmv227","volume":"54","author":"Z Zhu","year":"2016","unstructured":"Zhu Z, Yang S, Zhao W, Li R, Zhao C. A comparative pharmacokinetic study of myrislignan by UHPLC-MS after oral administration of a monomer and Myristica fragrans extract to rats. J Chromatogr Sci. 2016;54:689\u201396.","journal-title":"J Chromatogr Sci"},{"key":"2990_CR21","volume-title":"Guidance for industry: bioanalytical method validation","author":"US Food and Drug Administration","year":"2018","unstructured":"US Food and Drug Administration. Guidance for industry: bioanalytical method validation. Rockville: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; 2018."},{"key":"2990_CR22","first-page":"316","volume":"78","author":"C Gokbulut","year":"2014","unstructured":"Gokbulut C, Yalinkilinc HS, Aksit D, Veneziano V. Comparative pharmacokinetics of levamisole-oxyclozanide combination in sheep and goats following per os administration. Can J Vet Res. 2014;78:316\u201320.","journal-title":"Can J Vet Res"},{"issue":"1","key":"2990_CR23","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12917-019-1963-0","volume":"15","author":"J Zhang","year":"2019","unstructured":"Zhang J, Bai Y, Li B, Zhou X, Si H, Zhang J. Determination and pharmacokinetics study of oxyclozanide suspension in cattle by LC-MS\/MS. BMC Vet Res. 2019;15(1):210.","journal-title":"BMC Vet Res"},{"key":"2990_CR24","doi-asserted-by":"publisher","first-page":"e4007","DOI":"10.1002\/bmc.4007","volume":"31","author":"AA Kadi","year":"2017","unstructured":"Kadi AA, Alrabiah H, Attwa MW, Attia S, Mostafa GAE. Development and validation of HPLC-MS\/MS method for the determination of lixivaptan in mouse plasma and its application in a pharmacokinetic study. Biomed Chromatogr. 2017;31:e4007.","journal-title":"Biomed Chromatogr"},{"key":"2990_CR25","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/bmc.2821","volume":"27","author":"SJ Liu","year":"2013","unstructured":"Liu SJ, Zhou L, Zhang J, Yu BY, Li CY, Liu ZX, et al. Determination of limonin in dog plasma by liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. Biomed Chromatogr. 2013;27:515\u20139.","journal-title":"Biomed Chromatogr"},{"key":"2990_CR26","doi-asserted-by":"publisher","first-page":"e3825","DOI":"10.1002\/bmc.3825","volume":"31","author":"B Li","year":"2017","unstructured":"Li B, Gong SY, Zhou XZ, Yang YJ, Li JY, Wei XJ, et al. Determination of antibacterial agent tilmicosin in pig plasma by LC\/MS\/MS and its application to pharmacokinetics. Biomed Chromatogr. 2017;31:e3825.","journal-title":"Biomed Chromatogr"},{"key":"2990_CR27","unstructured":"ICH Harmonised Tripartite Guideline. Validation of analytical procedures: text and methodology Q2 (R1). In: International Conference on Harmonization (ICH) of technical requirements for registration of pharmaceuticals for human. Geneva: IFPMA; 2005. p.\u00a01\u201313."},{"key":"2990_CR28","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/bmc.2762","volume":"27","author":"Q Chen","year":"2013","unstructured":"Chen Q, Li P, Zhang J, Zhu J. Preclinical pharmacokinetic analysis of armillarisin succinate ester in mouse plasma and tissues by LC-MS\/MS. Biomed Chromatogr. 2013;27:130\u20136.","journal-title":"Biomed Chromatogr"},{"key":"2990_CR29","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.tvjl.2014.06.015","volume":"202","author":"D Klinkenberg","year":"2014","unstructured":"Klinkenberg D, Tobias TJ, Bouma A, van Leengoed LAMG, Stegeman JA. Simulation study of the mechanisms underlying outbreaks of clinical disease caused by Actinobacillus pleuropneumoniae in finishing pigs. Vet J. 2014;202:99\u2013105.","journal-title":"Vet J"},{"key":"2990_CR30","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jpba.2015.12.051","volume":"120","author":"W Chen","year":"2016","unstructured":"Chen W, Yeo SC, Chuang XF, Lin HS. Determination of pinostilbene in rat plasma by LC-MS\/MS: application to a pharmacokinetic study. J Pharm Biomed Anal. 2016;120:316\u201321.","journal-title":"J Pharm Biomed Anal"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-021-02990-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12917-021-02990-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-021-02990-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T09:09:05Z","timestamp":1629104945000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-021-02990-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,16]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2990"],"URL":"https:\/\/doi.org\/10.1186\/s12917-021-02990-y","relation":{},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,16]]},"assertion":[{"value":"16 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All of the authors declare the absence of any financial or personal interests that could have inappropriately influenced the current study. The final article has been approved by all of the authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was carried out in compliance with the ARRIVE guidelines. The study, executed by Dr. Jili Zhang and Dr. Jiyu Zhang, was conducted between March and April 2019 at the Lanzhou Institute of Husbandry and Pharmaceutical Sciences of Lanzhou, Gansu Province, China. Thirty-six mice were used in this study. All of the experimental methods, the animal care and the barn environment of this study strictly complied with the Guide for the Care and Use of Laboratory Animals, Lanzhou Institute of Husbandry and Pharmaceutical Sciences, China. In addition, all efforts were made to minimize suffering. Thus, we agreed to conduct the experiment, and the certificate number was SCXK (Gan) 2019\u20130010.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"275"}}